Search results
Results from the WOW.Com Content Network
An epinephrine autoinjector (or adrenaline autoinjector, also known by the trademark EpiPen) is a medical device for injecting a measured dose or doses of epinephrine (adrenaline) by means of autoinjector technology. It is most often used for the treatment of anaphylaxis. The first epinephrine autoinjector was brought to market in 1983.
Epi-pen, epinephrine in an auto injecting "pen" to counter anaphylactic (severe allergic) reactions. A combat medic is generally expected to care for the needs of the soldiers in his group, including their everyday ailments. A medic will usually carry a small amount of what are referred to as "snivel" or "sick call meds."
In 2023 an open source autoinjector was developed that could be digitally replicated with a low cost desktop 3D printer. [4] It was tested against the then current standard (ISO 11608–1:2022) [ 5 ] for needle-based injection systems and found to cost less than mass manufactured systems.
The first-ever needle-free alternative to the EpiPen and similar epinephrine autoinjectors has been approved by the Food and Drug Administration to treat anaphylaxis. Neffy, a nasal spray that ...
The US Food and Drug Administration approved the first nasal spray epinephrine drug for severe allergic reactions known as anaphylaxis, providing a needle-free alternative to EpiPens and similar ...
There is an epinephrine metered-dose inhaler sold over the counter in the United States to relieve bronchial asthma. [67] [68] It was introduced in 1963 by Armstrong Pharmaceuticals. [69] A common concentration for epinephrine is 2.25% w/v epinephrine in solution, which contains 22.5 mg/mL, while a 1% solution is typically used for aerosolization.
Prescription drug list prices in the United States continually are among the highest in the world. [ 1 ] [ 2 ] The high cost of prescription drugs became a major topic of discussion in the 21st century, leading up to the American health care reform debate of 2009, and received renewed attention in 2015.
Jul. 17—MORGANTOWN — Pfizer and two of its subsidiaries have agreed to a $345 million settlement in a four-year class-action antitrust lawsuit concerning Mylan's EpiPen.